| Literature DB >> 34697725 |
Mariana Guimarães1, Martin Kuentz2, Maria Vertzoni3, Nikoletta Fotaki4.
Abstract
PURPOSE: To understand drug solubilization as a function of age and identify drugs at risk of altered drug solubility in pediatric patients. To assess the discrimination ability of the Abraham solvation parameters and age-related changes in simulated media composition to predict in vitro drug solubility differences between pediatric and adult gastrointestinal conditions by multivariate data analysis.Entities:
Keywords: Abraham solvation parameters; Biorelevant; Multivariate analysis; Pediatric; Solubility
Mesh:
Year: 2021 PMID: 34697725 PMCID: PMC8688383 DOI: 10.1007/s11095-021-03123-8
Source DB: PubMed Journal: Pharm Res ISSN: 0724-8741 Impact factor: 4.200
Fig. 1Variables present in each PLS-R model investigated. Drug properties were maintained in every model and media properties were selected according to changes in media composition between pediatric and adult simulated GI fluids. Investigated interactions (between drug properties and media properties) are also described, where interactions coloured in purple represent interactions with VIP values lower than 0.7.
Drugs Investigated in this Study and Abraham Solvation Parameters (ACD/Absolv. Prediction Module 2016.1)
| Compound | logP | pKa (s) | A | Bo | S | E | V |
|---|---|---|---|---|---|---|---|
| Mesalazine | 0.98 ( | 2.3 (acidic) & 5.69 (basic) ( | 0.93 | 0.74 | 1.52 | 1.22 | 1.09 |
| Montelukast | 8.79 ( | 2.7 (basic) & 5.8 (acidic) ( | 0.88 | 1.68 | 2.86 | 3.75 | 4.49 |
| Nitrofurantoin | -0.47 ( | 7.2 (acidic) ( | 0.24 | 1.34 | 2.03 | 1.65 | 1.45 |
| Phenytoin | 1.92 ( | 8.06 (acidic) ( | 0.44 | 1.15 | 2.04 | 1.94 | 1.87 |
| Naproxen | 3.18 ( | 4.18 (acidic) ( | 0.57 | 0.76 | 1.49 | 1.54 | 1.78 |
| Indomethacin | 4.27 ( | 4.45 (acidic) ( | 0.57 | 1.26 | 2.49 | 2.44 | 2.53 |
| Dapsone | 0.97 ( | 3.2 (basic) ( | 0.45 | 1.35 | 1.42 | 9.71 | 2.84 |
| Dipyridamole | 2.74 ( | 5.7–6.4 (basic) ( | 0.95 | 3.03 | 2.95 | 20.53 | 2.90 |
| Mebendazole | 2.8 ( | 3.5 (basic) ( | 0.71 | 1.38 | 1.34 | 12.82 | 2.76 |
| Amiodarone | 7.57 ( | 8.73 (basic) ( | 0 | 1.30 | 1.31 | 18.09 | 2.49 |
| Griseofulvin | 2.18 ( | not applicable | 0 | 1.58 | 1.59 | 11.78 | 2.32 |
| Spironolactone | 2.26 ( | not applicable | 0 | 1.63 | 1.65 | 16.02 | 3.81 |
| Carbamazepine | 2.45 ( | not applicable | 0.39 | 0.92 | 0.94 | 10.79 | 2.06 |
| Fenofibrate | 5.3 ( | not applicable | 0 | 1.13 | 1.14 | 11.914 | 2.11 |
A hydrogen-bonding acidity; B hydrogen-bonding basicity; S dipolarity/polarizability; E excess molar refraction; and V McGowan characteristic volume
Fig. 2Standardized coefficients in pediatric fasted (a) and fed (b) gastric fluids, and pediatric fasted (c) and fed (d) intestinal fluids corresponding to the variables and interactions investigated in each model. Bars in dark blue denote coefficients of VIP ≥ 1.0 (significant impact), and bars of lighter blue represent variables with 1 ≥ VIP ≥ 0.7 (moderate impact), which are considered to have an effect on the response value Sp/Sa (%).